{"url":"https://newsforagent.com/news/2026-11-10/tecregen-svanberg-chief-medical-officer-hanke-board","markdown_url":"https://newsforagent.com/news/2026-11-10/tecregen-svanberg-chief-medical-officer-hanke-board.md","title":"TECregen Names Elisabeth Svanberg Chief Medical Officer","headline":"TECregen Appoints Elisabeth Svanberg as Chief Medical Officer and Thomas Hanke to Board","description":"TECregen appointed Elisabeth Svanberg as Chief Medical Officer and Thomas Hanke to its board, strengthening leadership.","section":"Leadership","published_at":"2026-11-10T08:52:23+00:00","modified_at":"2026-11-10T08:52:23+00:00","author":"News Desk","key_takeaways":["Elisabeth Svanberg, MD, PhD, was appointed Chief Medical Officer of TECregen.","Thomas Hanke, PhD, joined TECregen's Board of Directors, succeeding Martin Raditsch as CARMA FUND's representative.","TECregen is preparing its lead program TEC001 for IND-enabling development in uremia-associated immunodeficiency."],"companies":[{"name":"TECregen","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00kd8oj/tecregen","website":"https://www.tecregen.com"}],"source":{"publisher":"GlobeNewswire","title":"TECregen Strengthens Management Team and Board to Advance Thymus Regeneration and Lead Program TEC001","url":"https://www.globenewswire.com/news-release/2026/11/10/3399190/0/en/tecregen-strengthens-management-team-and-board-to-advance-thymus-regeneration-and-lead-program-tec001.html"},"other_sources":[],"tags":["Leadership","TECregen"],"body_markdown":"[TECregen](https://akta.pro/company-profiles/00kd8oj/tecregen) appointed Elisabeth Svanberg as Chief Medical Officer and Thomas Hanke to its Board of Directors, the company said in a [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/10/3399190/0/en/tecregen-strengthens-management-team-and-board-to-advance-thymus-regeneration-and-lead-program-tec001.html) announcement on November 10, 2026. Hanke succeeds Martin Raditsch as CARMA FUND's representative on the board.\n\n## Svanberg's Clinical Development Background\n\nSvanberg is a physician and biotechnology executive with more than 25 years of international experience in drug development, clinical strategy and medical leadership. She has held global leadership positions at Janssen Pharmaceuticals (Johnson & Johnson), Bristol Myers Squibb and Merck Serono, where she led clinical development programs, medical affairs activities for product launches and interactions with health authorities in the U.S., Europe and other major markets. She later served as Chief Development Officer at Ixaltis and Chief Medical Officer at Kuste Biopharma. Svanberg has board experience at Medincell, LEO Pharma and Galapagos, and served as Chair of EPICS Therapeutics. A board-certified surgeon and Associate Professor of Surgery, she holds an MD and a PhD from the University of Gothenburg, Sweden.\n\n\"Elisabeth joins TECregen at an important stage for the company as we prepare to take TEC001 through the next stage of preclinical development,\" said Dr. Klaas P. Zuideveld, Chief Executive Officer of TECregen. \"She brings first-hand experience of advancing innovative therapies through clinical development, as well as extensive experience working with regulators in the U.S. and Europe.\"\n\nSvanberg said: \"TECregen is tackling a significant unmet medical need by addressing the progressive loss of thymic function, the resulting reduction in the production of new naïve T cells and susceptibility to infection.\"\n\n## Hanke Brings Immunology and Drug Discovery Experience\n\nHanke is a Venture Partner at CARMA FUND and an immunobiologist with more than 30 years of early-stage R&D experience across academia, biotech and pharma. As Executive Vice President and Head of Academic Partnerships at Evotec, he built a global portfolio of academic alliances, pre-seed accelerators and equity investments, having previously led Evotec's discovery portfolio in inflammation and immuno-oncology. Before Evotec, he was Sourcing Director at Novo Nordisk, focused on autoimmune and inflammatory diseases. Hanke has co-initiated more than 160 drug discovery projects and 100 collaborations, partnerships and investments, and has served on the boards of Tubulis and Dark Blue Therapeutics.\n\n\"TECregen builds on a strong scientific rationale, a focused lead program and an experienced team with deep expertise in thymus biology and protein engineering,\" Hanke said.\n\n## TEC001's Path Toward Clinical Development\n\nTEC001 is an engineered version of keratinocyte growth factor (KGF or FGF7), a natural protein involved in thymus repair, designed to remain in the body longer and reach the thymus more directly than unmodified KGF. TECregen has selected TEC001 as its lead program for uremia-associated immunodeficiency (UAI), supported by preclinical studies showing dose-dependent increased thymic cellularity and naïve T-cell production. The company is preparing the program for IND-enabling development.\n\n## TECregen's Leadership and Funding Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), TECregen appointed Dr. Klaas P. Zuideveld as Chief Executive Officer in January 2026 to lead its transition into clinical development, and named Dr. Bo Rode Hansen, former CEO of Scandion Oncology and a veteran Roche and Santaris executive, as Chairman of the Board the same month. The same records show TECregen closed a CHF 10 million seed financing, equivalent to USD 12.6 million, led by Boehringer Ingelheim Venture Fund with six co-investors. The company is Basel-based, was founded in 2023 and has a headcount range of 1-10, according to the same records.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}